Abstract:<p>Bleeding resulting from the application of low-molecular-weight heparins (LMWHs) may be treated with protamine sulfate, but this treatment lacks efficiency; its action against antifactor Xa activity is limited to ~60%. Moreover, protamine sulfate can cause life-threatening hypersensitivity reactions. We developed diblock heparin-binding copolymer (HBC), which can neutralize the anticoagulant activity of parenteral anticoagulants. In the present study, we explored the safety profile of HBC and its potential to reverse enoxaparin, nadroparin, dalteparin, and tinzaparin in human plasma and at in vivo conditions. HBC-LMWH complexes were characterized using zeta potential, isothermal titration calorimetry, and dynamic light scattering. The rat cardiomyocytes and human endothelial cells were used for the assessment of in vitro toxicity. Male Wistar rats were observed for up to 4 days after HBC administration for clinical evaluation, gross necropsy, and biochemistry and histopathological analysis. Rats were treated with LMWHs alone or followed by short-time intravenous infusion of HBC, and bleeding time and antifactor Xa activity were measured. HBC completely reversed antifactor Xa activity prolonged in vitro by all LMWHs with an optimal weight ratio of 2.5:1. The complexes of HBC-LMWHs were below 5 µm. We observed no effects on the viability of cardiovascular cells treated with HBC at concentrations up to 0.05 mg/ml. Single doses up to 20 mg/kg of HBC were well tolerated by rats. HBC completely reversed the effects of LMWHs on bleeding time and antifactor Xa activity in vivo after 20 minutes and retained ~80% and ~60% of reversal activity after 1 and 2 hours, respectively. Well-documented efficacy and safety of HBC both in vitro and in vivo make this polymer a promising candidate for LMWHs reversal.</p>SIGNIFICANCE STATEMENT<p>Over the last decade, there has been significant progress in developing antidotes for the reversal of anticoagulants. Until now, there has been no effective and safe treatment for patients with severe bleeding under low-molecular-weight heparin therapy. Based on our in vitro and in vivo studies, heparin-binding copolymer seems to be a promising candidate for neutralizing all clinically relevant low-molecular-weight heparins.</p>

Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin

Comparison Of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin

Enzymatic synthesis of low molecular weight heparins from N-sulfo heparosan depolymerized by heparanase or heparin lyase

Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

A Unique Enoxaparin Derived from Bovine Intestinal Heparin: A Single Purification Step of the Starting Material Assures a Bovine Enoxaparin Like the Standard from Porcine Origin

Preparation of Low Molecular Weight Heparin Using an Ultrasound-Assisted Fenton-system

Correction: Evaluation of a Novel Thermosensitive Heparin-Poloxamer Hydrogel for Improving Vascular Anastomosis Quality and Safety in a Rabbit Model.

Research Progress of Low Molecular Weight Heparin

Immobilized high-performance heparin lyase III for efficient preparation of low molecular weight heparin

A quantitative mass spectrometry method to differentiate bovine and ovine heparins from pharmaceutical porcine heparin

Development of Low Molecular Weight Heparin by H2O2/ascorbic Acid with Ultrasonic Power and Its Anti-Metastasis Property.

Characteristics of low molecular weight heparin production by an ultrafiltration membrane bioreactor using maltose binding protein fused heparinase I

E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor

A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions

Analysis of heparinase derived LMWH products using a MHC 2D LC system linked to Q-TOF MS

Heparinase Digestion-Based Disaccharide Composition Analysis of Heparin and Heparinoid Drugs

Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats

High-Level Expression and Purification of Recombinant Heparinase Ⅰ in Escherichia Coli

Production of Heparin Oligosaccharides by Fusion Protein of MBP–heparinase I and the Enzyme Thermostability

Development of effective heparin extraction method from pig by-products and analysis of their bioavailability